Time to raise awareness regarding complications of androgen deprivation therapy

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2012,（2）
• 页码范围: 175-176
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.105

摘要

No treatment is devoid of adverse effects,and androgen deprivation therapy (ADT) in men with prostate cancer (PCa) bears no exception.PCa is the most common non-cutaneous malignancy in men worldwide.In 2011,approximately 240 890 new cases of PCa were diagnosed in the United States and 33 720 men died because of the disease.1 In intermediate- and high-risk patients with locally advanced disease,ADT,when added to external bean radiation therapy,has shown improved survival,while in men with metastatic PCa,ADT improves quality of life (QoL).2-4 However,patients with localized cancer and those encountering biochemical recurrences after definitive therapy are also being started on ADT,even though survival advantage has not been conclusively demonstrated in these clinical settings.As a result,the use of ADT has significantly increased in the last 15 years.